Hexagon Nutrition IPO GMP Today, Price & Details

Hexagon Nutrition works in the clinical and public-health nutrition space, making micronutrient premixes, food-fortification blends, and medical-nutrition products. It's a business with a genuine social-impact angle — fortifying staple foods and supplying nutrition programmes — alongside a commercial medical-nutrition arm. The IPO was a mainboard offering on the NSE, sized at ₹138.87 Cr and priced at ₹42–45 per share with a low face value of ₹1.

On the financials, the company reported revenue of ₹267.59 Cr and net profit of ₹27.03 Cr, with a steady EBITDA margin of 12.33% and reasonable return ratios of 12.46% RONW and 17.06% ROCE. It's a moderately profitable, specialised nutrition player rather than a high-flyer.

This was a 100% offer for sale of ₹138.87 Cr, so the money went to existing shareholders rather than into the company. For investors, that means no fresh growth capital — you're buying a stake in an established, niche business at its current run-rate.

At the upper band of ₹45, Hexagon was valued at 14.33x earnings on an EPS of ₹2.93 — a modest, undemanding multiple that stood out as one of the more reasonably priced offerings of the season. That value pricing was likely a big reason for the strong response.

The financial profile is steady rather than spectacular. A 12.33% EBITDA margin and 17.06% ROCE are respectable for a nutrition-products business, and revenue of ₹267.59 Cr gives it decent scale. The specialised, regulated nature of medical nutrition also provides a modest moat.

On the risk side, the 100% OFS structure means no fresh capital for expansion, and a chunk of the business depends on government and institutional nutrition programmes, which can be tender-driven and lumpy. Raw-material costs and regulatory approvals in the food-and-nutrition space are the other watch-items.

The market liked the value on offer. The issue was subscribed 161.49x overall, led by NII at 161.49x, with QIB at 19.77x and retail a strong 26.85x — and the stock duly listed with a healthy gain, opening at ₹48 against the ₹45 issue price. Our IPO profit calculator can size the per-lot returns. Investors should consult a SEBI-registered financial advisor before making investment decisions.

Disclaimer: This analysis is auto-generated from publicly available financial data and should not be considered investment advice. Always consult a SEBI-registered financial advisor before making investment decisions.